Cargando…

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

INTRODUCTION: While dose escalation of golimumab has been used for patients with rheumatoid arthritis who demonstrate an inadequate response to the standard dose, its effectiveness has not been fully evaluated. The aim of this study was to assess the clinical outcome observed by dose escalation of g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Hirohito, Kobayashi, Hisanori, Kanbori, Masayoshi, Ishii, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211224/ https://www.ncbi.nlm.nih.gov/pubmed/32114644 http://dx.doi.org/10.1007/s40744-020-00198-4

Ejemplares similares

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
por: Miyashiro, Masahiko, et al.
Publicado: (2023)

Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting
por: Yokoyama, Seiji, et al.
Publicado: (2022)

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
por: Krüger, Klaus, et al.
Publicado: (2020)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study
por: Tamura, Mina, et al.
Publicado: (2022)

Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
por: Shono, Eisuke
Publicado: (2013)

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis
por: Kurosawa, Yoichi, et al.
Publicado: (2022)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
por: Yamairi, Fumiko, et al.
Publicado: (2020)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study
por: Motoo, Nagane, et al.
Publicado: (2019)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2023)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Erratum for Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Tiered escalation response systems in practice: A post hoc analysis examining the workload implications
por: O'Connell, Alice, et al.
Publicado: (2023)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial
por: Nagano, Katsumasa, et al.
Publicado: (2022)

Safety and tolerability of agalsidase beta infusions shorter than 90 min in patients with Fabry disease: post-hoc analysis of a Japanese post-marketing study
por: Lee, Chae Sung, et al.
Publicado: (2023)

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
por: Sato, Kazuo, et al.
Publicado: (2018)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
por: Soubrier, Martin, et al.
Publicado: (2016)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
por: Kuroishi, Naho, et al.
Publicado: (2019)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database
por: Ziyadeh, Najat J., et al.
Publicado: (2020)

All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
por: Kobayashi, Mana, et al.
Publicado: (2021)

Escalating post-disaster rescue missions through ad-hoc victim localization exploiting Wi-Fi networks
por: Khan, Taslim Arefin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f55nm24i4n1ft932clenalp7ot